Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

NCT ID: NCT04907838

Last Updated: 2021-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-01

Study Completion Date

2021-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the role of endothelin in insulin stimulated vasodilation and glucose uptake. The subjects will complete an hyperinsulinemic euglycemic clamp with and without blockade of the endothelin receptors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 diabetics

BQ123 (25 nmol/min), BQ788 (25 nmol/min)

Group Type EXPERIMENTAL

Insulin clamp

Intervention Type DRUG

Continous infusion insulin + glucose

BQ123

Intervention Type DRUG

Continuous infusion of Insulin + glucose + BQ123

BQ123 + BQ788

Intervention Type DRUG

Continous infusion of insulin + glucose + BQ123 + BQ788

Healthy controls

BQ123 (25 nmol/min), BQ788 (25 nmol/min)

Group Type EXPERIMENTAL

Insulin clamp

Intervention Type DRUG

Continous infusion insulin + glucose

BQ123

Intervention Type DRUG

Continuous infusion of Insulin + glucose + BQ123

BQ123 + BQ788

Intervention Type DRUG

Continous infusion of insulin + glucose + BQ123 + BQ788

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin clamp

Continous infusion insulin + glucose

Intervention Type DRUG

BQ123

Continuous infusion of Insulin + glucose + BQ123

Intervention Type DRUG

BQ123 + BQ788

Continous infusion of insulin + glucose + BQ123 + BQ788

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes OR healthy control (no type 2 diabetes)
* BMI\<32

Exclusion Criteria

* heart disease
* pregnancy or birth within 3 month
* smoking
* Kidney disease
* beta-blockers
* insulin treatment (for type 2 diabetics)
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas at Arlington

OTHER

Sponsor Role collaborator

University of Southern Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefan Mortensen

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefan Mortensen, DMSc

Role: PRINCIPAL_INVESTIGATOR

Professor

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiovascular and Renal Research

Odense, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Young BE, Padilla J, Finsen SH, Fadel PJ, Mortensen SP. Role of Endothelin-1 Receptors in Limiting Leg Blood Flow and Glucose Uptake During Hyperinsulinemia in Type 2 Diabetes. Endocrinology. 2022 Mar 1;163(3):bqac008. doi: 10.1210/endocr/bqac008.

Reference Type DERIVED
PMID: 35084435 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

s-20180040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dose Response of Epinephrine
NCT02692313 COMPLETED EARLY_PHASE1
Insulin in Total Parenteral Nutrition
NCT02706119 COMPLETED PHASE4